MTCYBP35

Across TCGA pan-cancer cohorts, MTCYBP35 RNA is linked to patient survival in 23 of 34 cancer types, making it the most broadly survival-associated MTCYBP35 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher MTCYBP35 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTCYBP35 expression acts as an unfavorable survival marker, although some lineages such as ACC and BLCA show a favorable association.

CHOL, ACC, and BLCA are the cancer types where MTCYBP35 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Quartile	II,III,IV	0.246	0.663	.013	45	view →
ACC	DFS	Median	All	0.655	0.310	.002	38	view →
BLCA	DFS	Tertile	All	0.688	0.550	.001	36	view →
KICH	OS	Tertile	All	1.000	0.688	.015	32	view →
OV	OS	Quartile	III,IV	0.251	0.398	.013	14	view →
BRCA	OS	Quartile	IV	0.866	0.337	.012	13	view →
DLBC	OS	Median	IV	1.000	0.417	.013	10	view →
SKCM	DFS	Quartile	IV	0.855	0.086	.006	9	view →
LUSC	DFS	Quartile	III,IV	0.677	0.429	.023	8	view →
SARC	DFS	Median	All	0.476	0.292	.020	8	view →
PAAD	OS	Tertile	All	0.692	0.543	.034	6	view →
THCA	OS	Median	II,III,IV	1.000	0.651	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 23 lineages.

MTCYBP35–CHOL (OS)

Open the CHOL breakdown →